• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by X4 Pharmaceuticals Inc.

    3/26/25 6:12:43 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XFOR alert in real time by email
    S-8 1 a032025s-8.htm S-8 Document

    As filed with the Securities and Exchange Commission on March 25, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ____________________________________________
    X4 Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)
    ___________________________________________
    Delaware27-3181608
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    61 North Beacon Street, 4th Floor
    Boston, Massachusetts
    02134
    (Address of Principal Executive Offices)(Zip Code)
    X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan
    (Full title of the plan)

    Paula Ragan, Ph.D.
    President and Chief Executive Officer
    X4 Pharmaceuticals, Inc.
    61 North Beacon Street, 4th Floor
    Boston, Massachusetts 02134
    (857) 529-8300
    (Name, address and telephone number, including area code, of agent for service)
    _________________________________
    Copy to:
    Gabriela Morales-Rivera
    William D. Collins
    Goodwin Procter LLP
    100 Northern Avenue
    Boston, MA 02210
    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☒
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐















    INCORPORATION OF DOCUMENTS BY REFERENCE

    This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 of the Registrant relating to the same employee benefit plan is effective. Accordingly, pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8 (File No. 333-233162) filed with the Securities and Exchange Commission (“SEC”) on August 9, 2019 relating to the Registrant’s 2019 Inducement Equity Incentive Plan (as amended and restated from time to time, the “Inducement Plan”); (ii) the Registration Statement on Form S-8 (File No. 333-237164) filed with the SEC on March 13, 2020 relating to the Inducement Plan and certain other employee benefit plans of the Registrant; (iii) the Registration Statement on Form S-8 (File No 333-254618) filed with the SEC on March 23, 2021 relating to the Inducement Plan and certain other employee benefit plans of the Registrant; (iv) the Registration Statement on Form S-8 (File No 333-263430) filed with the SEC on March 10, 2022 relating to the Inducement Plan and certain other employee benefit plans of the Registrant; (v) the Registration Statement on Form S-8 (File No 333-269335) filed with the SEC on January 20, 2023 relating to the Inducement Plan and certain other employee benefit plans of the Registrant; (vi) the Registration Statement on Form S-8 (File No 333-273960) filed with the SEC on August 14, 2023 relating to the Inducement Plan and certain other employee benefit plans of the Registrant; and (vii) the Registration Statement on Form S-8 (File No 333-282513) filed with the SEC on October 4, 2024 relating to the Inducement Plan, in each case except for Item 8, Exhibits, with respect to which the Exhibit Index below is incorporated herein by reference.













    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 8. Exhibits

    The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
    Exhibit NumberExhibit DescriptionFiled HerewithIncorporated Reference herein from Form or ScheduleFiling DateSEC File/Reg. Number
    4.1
    Restated Certificate of Incorporation, as amended, as of September 1, 2022
    8-K
    (Exhibit 3.1)
    9/1/2022001-38295
    4.2
    Amended and Restated By-laws of the Registrant
    8-K
    (Exhibit 3.2)
    11/20/2017001-38295
    4.3
    Form of Common Stock Certificate
    8-K
    (Exhibit 4.1)
    03/13/2019001-38295
    5.1
    Opinion of Goodwin Procter LLP with respect to the legality of the securities being registered.
    X
    23.1
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm to X4 Pharmaceuticals, Inc.
    X
    23.2
    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)
    X
    99.1
    X4 Pharmaceuticals Inc. Amended and Restated 2019 Inducement Equity Incentive Plan
    S-8
    (Exhibit 99.2)
    8/14/2023001-38295
    99.2
    Form of Stock Option Agreement under the Amended and Restated 2019 Inducement Equity Incentive Plan
    8-K
    (Exhibit 10.2)
    6/19/2019001-38295
    99.3
    Form of Restricted Stock Agreement under Amended and Restated 2019 Inducement Equity Incentive Plan
    8-K
    (Exhibit 10.3)
    6/19/2019001-38295
    99.4
    Form of Restricted Stock Unit Agreement under the Amended and Restated 2019 Inducement Equity Incentive Plan
    8-K
    (Exhibit 10.4)
    6/19/2019001-38295
    107
    Filing Fee Table
    X



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on March 25, 2025.
    X4 PHARMACEUTICALS, INC.
    By: /s/ Paula Ragan, Ph.D.
    Paula Ragan, Ph.D.
    President and Chief Executive Officer

    SIGNATURES AND POWER OF ATTORNEY
    We, the undersigned officers and directors of X4 Pharmaceuticals, Inc., hereby severally constitute and appoint Paula Ragan, Ph.D. and Adam S. Mostafa, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of X4 Pharmaceuticals, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Paula Ragan
    President, Chief Executive Officer and Director
    (principal executive officer)
    March 25, 2025
    Paula Ragan, Ph.D.
    /s/ Adam S. Mostafa
    Chief Financial Officer and Treasurer
    (principal financial officer and principal accounting officer)
    March 25, 2025
    Adam S. Mostafa
    /s/ Michael S. WyzgaChairman of the Board of Directors, DirectorMarch 25, 2025
    Michael S. Wyzga
    /s/ William E. AliskiDirectorMarch 25, 2025
    William E. Aliski
    /s/ Gary J. BridgerDirectorMarch 25, 2025
    Gary J. Bridger, Ph.D.
    /s/ Francoise De CraeckerDirectorMarch 25, 2025
    Francoise De Craecker
    /s/ Alison F. LawtonDirectorMarch 25, 2025
    Alison F. Lawton
    /s/ David McGirrDirectorMarch 25, 2025
    David McGirr, M.B.A.
    /s/ Murray W. Stewart, M.D.DirectorMarch 25, 2025
    Murray W. Stewart, M.D.
    /s/ Robert K. WoodsDirectorMarch 25, 2025
    Robert K. Woods

    Get the next $XFOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XFOR

    DatePrice TargetRatingAnalyst
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    8/30/2023$3.00Buy
    B. Riley Securities
    12/22/2022$3.00Overweight
    Cantor Fitzgerald
    12/12/2022$3.00Overweight
    Piper Sandler
    12/14/2021$21.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $XFOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stewart Murray was granted 1,500 shares, increasing direct ownership by 23% to 7,883 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      6/10/25 4:30:52 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director De Craecker Francoise was granted 1,500 shares, increasing direct ownership by 47% to 4,722 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      6/10/25 4:30:44 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bridger Gary was granted 1,500 shares, increasing direct ownership by 47% to 4,722 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      6/10/25 4:30:32 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

      Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

      4/29/24 2:36:51 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      5/20/25 4:51:03 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Baldry Mark bought $19,252 worth of shares (35,050 units at $0.55) and was granted 600,000 shares, increasing direct ownership by 675% to 729,173 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:25 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care